Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 3
2004 1
2007 1
2009 1
2010 2
2011 3
2012 1
2013 3
2014 1
2015 3
2016 1
2017 2
2018 2
2020 3
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Results by year

Filters applied: . Clear all
Page 1
Blood immune cells as potential biomarkers predicting relapse-free survival of stage III/IV resected melanoma patients treated with peptide-based vaccination and interferon-alpha.
Moschella F, Buccione C, Ruspantini I, Castiello L, Rozo Gonzalez A, Iacobone F, Ferraresi V, Palermo B, Nisticò P, Belardelli F, Proietti E, Macchia I, Urbani F. Moschella F, et al. Front Oncol. 2023 May 18;13:1145667. doi: 10.3389/fonc.2023.1145667. eCollection 2023. Front Oncol. 2023. PMID: 37274275 Free PMC article.
Nicotinamide inhibits melanoma in vitro and in vivo.
Scatozza F, Moschella F, D'Arcangelo D, Rossi S, Tabolacci C, Giampietri C, Proietti E, Facchiano F, Facchiano A. Scatozza F, et al. Among authors: moschella f. J Exp Clin Cancer Res. 2020 Oct 7;39(1):211. doi: 10.1186/s13046-020-01719-3. J Exp Clin Cancer Res. 2020. PMID: 33028392 Free PMC article.
Clinical and Immunological Outcomes in High-Risk Resected Melanoma Patients Receiving Peptide-Based Vaccination and Interferon Alpha, With or Without Dacarbazine Preconditioning: A Phase II Study.
Urbani F, Ferraresi V, Capone I, Macchia I, Palermo B, Nuzzo C, Torsello A, Pezzotti P, Giannarelli D, Pozzi AF, Santaquilani M, Roazzi P, Bastucci S, Catricalà C, La Malfa A, Vercillo G, Gualtieri N, Buccione C, Castiello L, Cognetti F, Nisticò P, Belardelli F, Moschella F, Proietti E. Urbani F, et al. Among authors: moschella f. Front Oncol. 2020 Mar 6;10:202. doi: 10.3389/fonc.2020.00202. eCollection 2020. Front Oncol. 2020. PMID: 32211314 Free PMC article.
Disruption of IFN-I Signaling Promotes HER2/Neu Tumor Progression and Breast Cancer Stem Cells.
Castiello L, Sestili P, Schiavoni G, Dattilo R, Monque DM, Ciaffoni F, Iezzi M, Lamolinara A, Sistigu A, Moschella F, Pacca AM, Macchia D, Ferrantini M, Zeuner A, Biffoni M, Proietti E, Belardelli F, Aricò E. Castiello L, et al. Among authors: moschella f. Cancer Immunol Res. 2018 Jun;6(6):658-670. doi: 10.1158/2326-6066.CIR-17-0675. Epub 2018 Apr 5. Cancer Immunol Res. 2018. PMID: 29622580
Intratumoral injection of IFN-alpha dendritic cells after dacarbazine activates anti-tumor immunity: results from a phase I trial in advanced melanoma.
Rozera C, Cappellini GA, D'Agostino G, Santodonato L, Castiello L, Urbani F, Macchia I, Aricò E, Casorelli I, Sestili P, Montefiore E, Monque D, Carlei D, Napolitano M, Rizza P, Moschella F, Buccione C, Belli R, Proietti E, Pavan A, Marchetti P, Belardelli F, Capone I. Rozera C, et al. Among authors: moschella f. J Transl Med. 2015 May 2;13:139. doi: 10.1186/s12967-015-0473-5. J Transl Med. 2015. PMID: 25933939 Free PMC article. Clinical Trial.
25 results